Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US study

Journal of Clinical Microbiology

Volumn 45, Issue 2, 2007, Pages 290-293

  Farrell, David J ^a   File, Thomas M ^b   Jenkins, Stephen G ^c  

^a GR Micro Ltd   (United Kingdom)

^b SUMMA HEALTH SYSTEM   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; KETOLIDE; MACROLIDE; TELITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; ERM GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENOTYPE PHENOTYPE CORRELATION; IN VITRO STUDY; LONGITUDINAL STUDY; MEF A GENE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; POPULATION SURVEILLANCE; PREVALENCE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

STREPTOCOCCUS PNEUMONIAE;

EID: 33847043888     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01653-06     Document Type: Article

References (18)

1. Clinical and Laboratory Standards Institute. 2003. Document M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2005. Document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Farrell, D. J., I. Morrissey, S. Bakker, and D. Felmingham. 2001. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridisation. J. Antimicrob. Chemother. 48:541-544.
4. Farrell, D. J., S. J. Jenkins, S. D. Brown, M. Patel, B. S. Lavin, and K. P. Klugman. 2005. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11:851-858.
5. Farrell, D. J., I. Morrissey, S. Bakker, L. Morris, S. Buckridge, and D. Felmingham. 2004. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J. Clin. Microbiol. 42:764-768.
6. 5a. Farrell, D. J., et al. 2005. Abstr. 15th Eur. Cong. Clin. Microbiol. Infect. Dis., abstr. P1028.
7. Hoban, D. J., A. K. Wierzbowski, K. Nichol, and G. G. Zhanel. 2001. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob. Agents Chemother. 45:2147-2150.
8. Hoffman, H. L., M. E. Klepser, E. J. Ernst, C. R. Petzold, L. M. Sa'adah, and G. V. Doern. 2003. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob. Agents Chemother. 47:739-746.
9. 7a. Kays, M. B., and S. Brown. 2004. Abstr. Infect. Dis. Soc. Am. Ann. Meet., abstr. 354.
10. Klugman, K. P., and J. R. Lonks. 2005. Hidden epidemic of macrolide-resistant pneumococci. Emerg. Infect. Dis. 11:802-807.
11. Lonks, J. R., J. Garau, L. Gomez, M. Xercavins, A. Ochoa de Echaguen, I. F. Gareen, P. T. Reiss, and A. A. Medeiros. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35:556-564.
12. Mera, R. M., L. A. Miller, J. J. Daniels, J. G. Weil, and A. R. White. 2005. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn. Microbiol. Infect. Dis. 51:195-200.
13. Noreddin, A. M., D. Roberts, K. Nichol, A. Wierzbowski, D. J. Hoban, and G. G. Zhanel. 2002. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(E)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob. Agents Chemother. 46:4029-4034.
14. Shackcloth, J., L. Williams, and D. J. Farrell. 2004. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators. J. Infect. 48:229-235.
15. Shortridge V. D., G. V. Doern, A. B. Brueggemann, J. M. Beyer, and R. K. Flamm. 1999. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin. Infect. Dis. 29: 1186-1188.
16. Van Kerkhoven, D., W. E. Peetermans, L. Verbist, and J. Verhaegen. 2003. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J. Antimicrob. Chemother. 51:691-696.
17. Zhanel, G. G., M. DeCorby, A. Noreddin, C. Mendoza, A. Cumming, K. Nichol, A. Wierzbowski, and D. J. Hoban. 2003. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J. Antimicrob. Chemother. 52:83-88.
18. Zhanel, G. G., M. Dueck, D. J. Hoban, L. Vercaigne, J. Embil, A. S. Gin, and J. A. Karlowsky. 2001. Macrolides and ketolides: a review focusing on respiratory infections. Drugs 61:443-498.